Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
725.50 GBX | -0.34% | +1.04% | -38.78% |
09-05 | Transcript : Indivior PLC Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 10:45 AM | |
09-04 | Indivior reports "disappointing" results for study with Aelis Farma | AN |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 785M | 647M | 791M | 901M | 1.09B | |||||
Total Revenues | 785M | 647M | 791M | 901M | 1.09B | |||||
Cost of Goods Sold, Total | 140M | 92M | 127M | 159M | 186M | |||||
Gross Profit | 645M | 555M | 664M | 742M | 907M | |||||
Selling General & Admin Expenses, Total | 390M | 427M | 425M | 461M | 543M | |||||
R&D Expenses | 53M | 40M | 52M | 72M | 106M | |||||
Other Operating Expenses | - | - | - | -3M | -2M | |||||
Other Operating Expenses, Total | 443M | 467M | 477M | 530M | 647M | |||||
Operating Income | 202M | 88M | 187M | 212M | 260M | |||||
Interest Expense, Total | -20M | -17M | -18M | -22M | -30M | |||||
Interest And Investment Income | 24M | 7M | 1M | 18M | 43M | |||||
Net Interest Expenses | 4M | -10M | -17M | -4M | 13M | |||||
Other Non Operating Income (Expenses) | - | 0 | 3M | 1M | -1M | |||||
EBT, Excl. Unusual Items | 206M | 78M | 173M | 209M | 272M | |||||
Restructuring Charges | -20M | -11M | 1M | - | - | |||||
Gain (Loss) On Sale Of Assets | - | - | 20M | - | - | |||||
Asset Writedown | - | - | - | - | - | |||||
Insurance Settlements | - | - | 12M | 5M | 1M | |||||
Legal Settlements | -10M | -235M | -14M | -303M | -247M | |||||
Other Unusual Items | 4M | -5M | -2M | -6M | -25M | |||||
EBT, Incl. Unusual Items | 180M | -173M | 190M | -95M | 1M | |||||
Income Tax Expense | 46M | -25M | -15M | -42M | -1M | |||||
Earnings From Continuing Operations | 134M | -148M | 205M | -53M | 2M | |||||
Net Income to Company | 134M | -148M | 205M | -53M | 2M | |||||
Net Income - (IS) | 134M | -148M | 205M | -53M | 2M | |||||
Net Income to Common Incl Extra Items | 134M | -148M | 205M | -53M | 2M | |||||
Net Income to Common Excl. Extra Items | 134M | -148M | 205M | -53M | 2M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.92 | -1.01 | 1.41 | -0.38 | 0.01 | |||||
Basic EPS - Continuing Operations | 0.92 | -1.01 | 1.41 | -0.38 | 0.01 | |||||
Basic Weighted Average Shares Outstanding | 146M | 147M | 146M | 139M | 137M | |||||
Net EPS - Diluted | 0.9 | -1.01 | 1.35 | -0.38 | 0.01 | |||||
Diluted EPS - Continuing Operations | 0.9 | -1.01 | 1.35 | -0.38 | 0.01 | |||||
Diluted Weighted Average Shares Outstanding | 151M | 147M | 154M | 139M | 142M | |||||
Normalized Basic EPS | 0.88 | 0.33 | 0.74 | 0.94 | 1.24 | |||||
Normalized Diluted EPS | 0.85 | 0.33 | 0.7 | 0.94 | 1.2 | |||||
Dividend Per Share | - | - | - | - | - | |||||
Payout Ratio | - | - | - | - | - | |||||
American Depositary Receipts Ratio (ADR) | 1 | 1 | 1 | 1 | 1 | |||||
Supplemental Items | ||||||||||
EBITDA | 214M | 101M | 199M | 223M | 269M | |||||
EBITA | 207M | 94M | 193M | 217M | 262M | |||||
EBIT | 202M | 88M | 187M | 212M | 260M | |||||
EBITDAR | - | - | - | - | - | |||||
Effective Tax Rate - (Ratio) | 25.56 | 14.45 | -7.89 | 44.21 | -100 | |||||
Total Current Taxes | 38M | 8M | 3M | 64M | 55M | |||||
Total Deferred Taxes | 8M | -33M | -18M | -106M | -56M | |||||
Normalized Net Income | 129M | 48.75M | 108M | 131M | 170M | |||||
Interest on Long-Term Debt | 3M | 3M | 2M | 2M | 3M | |||||
Non-Cash Pension Expense | - | 1M | - | - | - | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 53M | 40M | 52M | 72M | 106M | |||||
Net Rental Expense, Total | - | - | - | - | - | |||||
Imputed Operating Lease Interest Expense | - | - | - | - | - | |||||
Imputed Operating Lease Depreciation | - | - | - | - | - | |||||
Stock-Based Comp., Other (Total) | 3M | 8M | 11M | 16M | 22M | |||||
Total Stock-Based Compensation | 3M | 8M | 11M | 16M | 22M |